Shandong Weigao Group Medical Polymer Company Limited provided earnings guidance for the year ended 31 December 2023. For the year, the company expects to record a decrease in revenue in the range of 2% to 5% during the Reporting Period as compared with the revenue recognised due to the accounting restatement as a result of business combination under common control for the same period last year; and a decrease of net profit attributable to the owners of the Company for the Reporting Period in the range of 25% to 30% as compared with the Net Profit reported with consideration of the accounting restatement as a result of business combination under common control for the same period last year.